Skip to main content

Table 1 Demographic data

From: The impact of intravenous iron supplementation in elderly patients undergoing major surgery

   A
(n = 1,364)
A, ID+, T+
(n = 36)
A+
(n = 576)
A+, ID+, T+
(n = 215)
Age 73.6 (± 5.8) 74 (± 5.4) 75.1 (± 6.2) 76.3 (± 6.3)
Gender (female) 28.4%
(n = 388)
54.1%
(n = 20)
25.5%
(n = 150)
42.6%
(n = 95)
BMI 27.1 (± 4.8) 24.6 (± 4.7) 26.4 (± 5.1) 26.5 (± 4.6)
ASA I-II 17.9%
(n = 244)
21.6%
(n = 8)
6.8%
(n = 39)
6.9%
(n = 15)
  III-IV 81.9%
(n = 1,117)
78.4%
(n = 28)
92.3%
(n = 532)
92.2%
(n = 198)
  V 0.2%
(n = 3)
0%
(n = 0)
0.9%
(n = 5)
0.9%
(n = 2)
Surgical discipline     
  Cardiac thoracic surgery 52.3%
(n = 713)
37.8%
(n = 13)
44.7%
(n = 258)
36.3%
(n = 78)
  Urology 17.8%
(n = 243)
13.5%
(n = 5)
8.0%
(n = 46)
7.2%
(n = 16)
  Vascular surgery 13.3%
(n = 181)
13.5%
(n = 5)
20.7%
(n = 119)
25.1%
(n = 54)
  Visceral surgery 11.7%
(n = 160)
24.3%
(n = 9)
21.9%
(n = 126)
27.8%
(n = 60)
  Maxillofacial surgery 4.4%
(n = 60)
10.8%
(n = 4)
2.0%
(n = 12)
3.1%
(n = 6)
  Orthopaedic/trauma surgery 0.4%
(n = 6)
0%
(n = 0)
2.4%
(n = 14)
0.4%
(n = 1)
  Gynaecology 0.1%
(n = 1)
0%
(n = 0)
0.2%
(n = 1)
0%
(n = 0)
Preoperative Hb (g/dl) a 14.2 (± 1.1) 13.2 (± 0.9) 11.1 (± 1.3) 10.6 (± 1.5)
  14.1(13.4; 14.9) 13.2 (12.5; 13.6) 11.3 (10.4; 12.2) 11 (9.6; 11.8)
  female 13.4 (± 1) 12.9 (± 0.8) 10.6 (± 1.1) 10.5 (± 1.4)
   13.3 (12.7; 14) 12.7 (12.3; 13.6) 10.8 (10; 11.4) 10.8 (9.6; 11.5)
  male 14.5 (± 1) 13.6 (± 0.8) 11.3 (± 1.3) 10.7 (± 1.5)
   14.4 (13.7; 15.1) 13.4 (13; 13.7) 11.5 (10.6; 12.4) 11.1 (9.6; 12)
  1. aHb haemoglobin, first Hb level in the course of treatment